Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 999
- Registration Number
- NCT00791258
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
- Conditions
- HypertensionDiabetes Mellitus
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 860
- Registration Number
- NCT00787605
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT00776646
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
- Conditions
- ObesityHypertension
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 188
- Registration Number
- NCT00775814
Vascular Improvement With Olmesartan Medoxomil Study
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 100
- Registration Number
- NCT00772499
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Essential Hypertension ( Mild to Moderate)
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1191
- Registration Number
- NCT00765674
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 451
- Registration Number
- NCT00760266
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Regression of Fatty Heart by Valsartan Therapy
- Conditions
- Metabolic SyndromeLipotoxicity
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00745953
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
- Conditions
- HypertensionType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 231
- Registration Number
- NCT00744237
- Locations
- 🇺🇸
Forest Investigative Site 49, Tustin, California, United States
🇺🇸Forest Investigative Site 32, Pembroke Pines, Florida, United States
🇺🇸Forest Investigative Site 081, Pembroke Pines, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.